Golimumab Gets FDA Nod for Two New Indications Golimumab Gets FDA Nod for Two New Indications

The TNF-alpha inhibitor significantly improved the signs and symptoms of psoriatic arthritis and ankylosing spondylitis in phase 3 testing.FDA Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Rheumatology News Alert Source Type: news